| 1. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S et al.. (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.. J Med Chem, 51 (20): (6581-91). [PMID:18800822] |
| 2. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A et al.. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.. Proc Natl Acad Sci USA, 105 (44): (17079-84). [PMID:18971340] |
| 3. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N et al.. (2015) DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.. N Engl J Med, 373 (18): (1697-708). [PMID:26510020] |
| 4. Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C et al.. (2018) Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.. Lancet Oncol, 19 (7): (975-986). [PMID:29880291] |
| 5. Ma Y, He L, Huang Q, Zheng S, Zhang Z, Li H, Liu S. (2018) Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.. BMC Med Genet, 19 (1): (185). [PMID:30333000] |
| 6. Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML et al.. (2018) Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.. J Immunother Cancer, 6 (1): (141). [PMID:30514390] |
| 7. Buisson R, Dion-Côté AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY. (2010) Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.. Nat Struct Mol Biol, 17 (10): (1247-54). [PMID:20871615] |
| 8. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.. Cancer Res, 72 (21): (5588-99). [PMID:23118055] |
| 9. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN. (2014) Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.. Nat Rev Drug Discov, 13 (6): (419-31). [PMID:24833294] |
| 10. Weimin Fang, Jinghao Wang, Xiaocong Ma, Ni Shao, Kunlin Ye, Dong Zhang, Changzheng Shi, Liangping Luo. (2023) A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer. International Journal of Nanomedicine, [PMID:37901361] |
| 11. Teng Wang, Jiaojiao Tao, Bingjie Wang, Tianze Jiang, Xia Zhao, Yang Yu, Xin Meng. (2023) Reversing Resistance of Cancer Stem Cells and Enhancing Pdt Based on Hyaluronic Acid Nanomicelles for Preventing Cancer Recurrence and Metastasis. Advanced Healthcare Materials, (9): (2302597). [PMID:37941492] |
| 12. Teng Wang, Yang Yu, Bingjie Wang, Tianze Jiang, Xin Meng, Xia Zhao. (2023) Photothermal hyaluronic acid composite hydrogel targeting cancer stem cells for inhibiting recurrence and metastasis of breast cancer. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 252 (126358). [PMID:37598824] |
| 13. Yang Yu, Teng Wang, Xin Meng, Tianze Jiang, Xia Zhao. (2023) Chitosan Thermosensitive Hydrogel Based on DNA Damage Repair Inhibition and Mild Photothermal Therapy for Enhanced Antitumor Treatment. BIOMACROMOLECULES, [PMID:37506051] |
| 14. Huiling Zhou, Chenxin Duan, Huimin Qin, Chaonan Huang, Jingxuan Hou, Yanming Chen, Jin Zhu, Cangcang Xu, Jian Jin, Tao Zhuang. (2023) Synthesis and structural characterization of a novel palbociclib-kaempferol cocrystal with improved tabletability and synergistic antitumor activity. JOURNAL OF MOLECULAR STRUCTURE, 1281 (135101). [PMID:] |
| 15. Ren-Jiang Kong, Xin-Yu Li, Jia-Qi Huang, Xiang Zhou, Fu-An Deng, Yan-Mei Li, Ling-Shan Liu, Shi-Ying Li, Hong Cheng. (2022) A self-delivery photodynamic sensitizer for enhanced DNA damage by PARP inhibition. Biomaterials Science, 11 (1): (162-169). [PMID:36398488] |
| 16. Chenxin Duan, Yanming Chen, Yuxin Zhang, Feifei Liang, Wenwen Liu, Xinyi Xiao, Cangcang Xu, Tao Zhuang, Chao Hao, Yin Chen. (2022) Two Cocrystals of Olaparib with Flavonoids toward Sustained Release: Structure, Dissolution Behavior, and Anticancer Activity Analysis. CRYSTAL GROWTH & DESIGN, 22 (8): (4885–4894). [PMID:] |
| 17. Huiping Hu, Yu Zhang, Wenting Ji, Hao Mei, Tingting Wu, Zihao He, Kaiping Wang, Chen Shi. (2022) Hyaluronic acid-coated and Olaparib-loaded PEI − PLGA nanoparticles for the targeted therapy of triple negative breast cancer. JOURNAL OF MICROENCAPSULATION, 39 (1): (25-36). [PMID:34859741] |
| 18. Jiejie Sun, Jingzhou Liu, Chunhong Gao, Jinpeng Zheng, Jinbang Zhang, Yaning Ding, Wei Gong, Meiyan Yang, Zhiping Li, Yuli Wang, Yang Yang, Chunsheng Gao. (2022) Targeted delivery of PARP inhibitors to neuronal mitochondria via biomimetic engineered nanosystems in a mouse model of traumatic brain injury. Acta Biomaterialia, 140 (573). [PMID:34958970] |
| 19. Meng Ding, Lei Xu, Yumeng Zhang, Wei Li, Yuqing Zhao. (2021) Simultaneous quantification and ADME prediction of AD-1 and its eight metabolites in rat feces, and screening of PARP-1 inhibitors through molecular docking. JOURNAL OF MOLECULAR STRUCTURE, 1244 (131016). [PMID:] |
A2306817